We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ANALYSIS OF PATIENTS IN THE FIRST RELAPSE OR PROGRESSION OF T‐CELL LYMPHOMA. REAL WORLD DATA FROM CZECH LYMPHOMA STUDY GROUP REGISTRY (NIHIL).
- Authors
Janikova, A.; Belada, D.; Klanova, M.; Chloupkova, R.; Kopalova, N.; Campr, V.; Kamaradova, K.; Prochazka, V.; Benesova, K.; Mocikova, H.; Duras, J.; Trneny, M.
- Abstract
The prognosis of relapsed/ progressed disease is much worse, but there are sporadic data about this group of patients only. Patients with early relapse (<1 year) with median age (61 yrs), 65% were men, median OS2 was 0.31 year (0-8.9); median interval from-relapse- to-therapy was 8 days (range; 0-370). The most frequent therapy administered in R1 were platinum-based (28%) a gemcitabine-based (16%) regimen, 40 (13.6%) pts were transplanted (including 20 alloTx); whereas 26% patients did not start any therapy.
- Subjects
T-cell lymphoma; DISEASE relapse; LYMPHOMAS; CUTANEOUS T-cell lymphoma; HEMATOLOGIC malignancies; NON-Hodgkin's lymphoma
- Publication
Hematological Oncology, 2023, Vol 41, p764
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3165_610